omniture
Kangpu Biopharmaceuticals, Ltd.

Latest News

Kangpu to Present Latest Study Results of epaldeudomide (KPG-818) at the 67th ASH Annual Meeting

HEFEI, China, Nov. 18, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that the comp...

2025-11-18 21:00 759

Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE

HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that t...

2025-04-28 20:00 1591

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

HEFEI, China, Feb. 25, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announ...

2025-02-25 21:00 1914

Kangpu Completed Bridging Clinical Study of KPG-818 in China

HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company ba...

2024-09-20 20:00 2448

Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster...

2024-06-10 20:00 2352

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that the U.S. ...

2024-06-05 19:00 2394

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company ded...

2024-02-20 20:00 1801

Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus

SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based i...

2022-06-13 09:00 2283